Sugammadex–rocuronium complex

The Sugammadex–rocuronium complex is a stable, 1:1 host-guest inclusion complex formed when the selective relaxant binding agent sugammadex encapsulates the aminosteroid neuromuscular blocking agent rocuronium [1.1.1, 1.2.3]. This complexation occurs via non-covalent hydrophobic and electrostatic interactions, effectively trapping the rocuronium molecule within the modified gamma-cyclodextrin cavity of sugammadex [1.2.3, 1.2.5]. The formation of this complex rapidly reduces the concentration of free rocuronium in the plasma, creating a concentration gradient that promotes the dissociation of rocuronium from nicotinic acetylcholine receptors at the neuromuscular junction [1.1.1, 1.3.2]. This process results in the rapid and predictable reversal of neuromuscular blockade, allowing for the restoration of muscle function and spontaneous breathing in patients post-surgery [1.1.2, 1.3.5]. The complex is pharmacologically inactive and is primarily eliminated from the body through renal excretion [1.1.4, 1.3.3]. Clinical considerations include the potential for displacement by other drugs like toremifene and the need for dose adjustments based on the depth of the blockade and the patient's renal status [1.2.1, 1.3.2].

Other names

Rocuronium–sugammadex complexSugammadex–rocuronium inclusion complexBridion–rocuronium complex

Sugammadex encapsulates rocuronium in a 1:1 ratio within its hydrophobic cavity, forming a stable inclusion complex that reduces free rocuronium levels in plasma and facilitates its removal from the neuromuscular junction [1.1.1, 1.2.3].